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Embryonic stem cells (ESCs) possess two unique characteristics: infinite 
self-renewal and the potential to differentiate into almost every cell type 
(pluripotency). Recently, global expression analyses of metastatic breast and 
lung cancers revealed an ESC-like expression program or signature, 
specifically for cancers that are mutant for p53 function. Surprisingly, although 
p53 is widely recognized as the guardian of the genome, due to its roles in cell 
cycle checkpoints, programmed cell death or senescence, relatively little is 
known about p53 functions in normal cells, especially in ESCs. My hypothesis 
is that p53 has specific transcription regulatory functions in human ESCs 
(hESCs) that a) oppose pluripotency and b) protect the stem cell genome in 
response to DNA damage and stress signaling.  In mouse ESCs, these roles 
are believed to coincide, as p53 promotes differentiation in response to DNA 
damage, but this is unexplored in hESCs.  
 To determine the biological roles of p53, specifically in hESCs, we mapped 
genome-wide chromatin interactions of p53 by chromatin immunoprecipitation 
and massively parallel tag sequencing (ChIP-Seq), and did so under three 
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different conditions of hESC status: pluripotency, differentiation-initiated and 
DNA-damage-induced. ChIP-Seq showed that p53 is enriched at distinct, 
induction-specific gene loci during each of these different conditions. Microarray 
gene expression analysis and functional annotation of the distinct p53-target 
genes revealed that p53 regulates specific genes encoding developmental 
regulators, which are expressed in differentiation-initiated but not DNA-
damaged hESCs. We further discovered that, in response to differentiation 
signaling, p53 binds regions of chromatin that are repressed but also poised for 
rapid activation by core pluripotency factors OCT4 and NANOG in pluripotent 
hESCs. In response to DNA damage, genes associated with migration and 
motility are targeted by p53; whereas, the prime targets of p53 in control of cell 
death are conserved for p53 regulation in both differentiation and DNA damage.   
 Our genome-wide profiling and bioinformatics analyses show that p53 
occupies a special set of developmental regulatory genes during early 
differentiation of hESCs and functions in an induction-specific manner. In 
conclusion, our research unveiled previously unknown functions of p53 in ESC 
biology, which augments our understanding of one of the most deregulated 
proteins in human cancers. 
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CHAPTER 1 INTRODUCTION 
1.1 Pluripotent stem cells 
1.1.1  Human Embryonic Stem Cells 
Human Embryonic Stem Cells (hESCs) are derived from inner cell mass 
of blastocyst-stage embryo [1] and possess two unique properties together: 
• Pluripotency: ability to differentiate into any somatic cell type. 
• Self-renewal: ability to reproduce indefinitely by staying in the same state  
(without losing pluripotency characteristics). 
Unraveling the molecular mechanisms that preserve ESC properties is 
important for understanding development, how the ground state is maintained 
and what are the reasons for developmental disorders; studying tissue 
differentiation, how the genome is regulated for lineage-specific differentiation; 
and generating the necessary knowledge to manipulate hESCs as an 
invaluable tool for regenerative medicine. Over the past decade, a global effort 
has been underway to deconstruct molecular mechanisms that underlie 
pluripotency in order to realize and harness the full potential of hESCs. The 
combined results from genetic, biochemical and genomic studies have revealed 
an intricate regulatory circuitry of pluripotent state, which contains transcription 
factors, chromatin regulators, non-coding RNAs and signaling molecules [2,3,4]. 
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1.1.2 ESC-specific Transcription factors 
Transcription factors can interact with the chromatin through their DNA-
binding domains that recognize specific DNA sequences (motifs) [5,6]. These 
proteins can induce the transcription of coding/non-coding genes while 
repressing the expression of others and are an important part of the regulatory 
circuitry. In hESCs, three core (master/key) transcription factors, OCT4 
(Pou5f1), SOX2 and NANOG (collectively abbreviated as OSN) act in coherent 
circuits to maintain the pluripotent state [7]. Functional studies identified Oct4 
and Nanog as master regulators by their unique expression patterns: enriched 
in the pluripotent state and reduced as ESCs undergo differentiation [8,9,10,11]. 
Oct4 and Sox2 form a heterodimer and bind to the DNA hence Sox2 is placed 
among the key regulators [12,13], although expression of Sox2 is also observed 
in some somatic cell types [14]. 
An “interconnected autoregulatory loop” emerged from genome-wide 
binding studies whereby the master regulators occupy their own promoters and 
reciprocally bind to the promoters of other key factors in order to regulate each 
other [15]. Oct4:Sox2 and Nanog also bind a major portion of coding/non-
coding gene promoters along with several hundred intergenic regions, including 
enhancers for pluripotency related genes. Integration of global gene expression 
data with OSN binding sites revealed that these factors are involved in 
transcriptional regulation of both active and repressed genes [15,16]. The ability 
to affect either repression or activation by the same transcription factors may be 
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due to context-specific co-factors that are recruited along with these key factors. 
One subset of actively expressed targets in ESCs is genes that are essential to 
maintain pluripotency and self-renewal where Oct4, Sox2 and Nanog bind 
together with co-activators or activating chromatin regulators, e.g. components 
of the Trithorax Complex. Transcriptionally silent, OSN gene-targets are 
enriched in developmental and differentiation regulators, as well as several 
lineage-specific genes. In this case, Oct4, Sox and Nanog repress gene 
expression by facilitating the binding of chromatin modifiers such as SetDB1 or 
Polycomb complex proteins that mark the chromatin around the regulatory 
sequences of silenced genes with repressive histone marks [17]. 
Several other transcription factors have been shown to play important 
roles in the regulation of pluripotency, but not all of these are conserved 
between mouse and human ESCs. Sall4 and Tcf3 are shown to target most of 
the genes that are bound by the key factors [2,18,19,20]. Other transcription 
regulators including Smad1, Ronin, Klf4, PRDM14, Tbx3, Esrrb and Trim28 are 
also implicated in maintaining pluripotency and controlling ESC state 
[2,20,21,22]. 
 
1.1.3 Chromatin regulators 
The eukaryotic genome is wrapped around highly conserved histone 
protein bundles (nucleosomes) to achieve compression of this long string of 
DNA into the nucleus, creating a higher-order DNA-protein complex called 
chromatin [23]. Nucleosome structure around a certain region has been shown 
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to affect the accessibility of underlying genomic elements (promoters, 
enhancers) thereby influences gene expression, DNA replication, DNA repair 
and others [24]. Several studies showed that certain sets of chromatin 
modifying enzymes contribute to the stability of pluripotency: whereas, others 
influence the establishment of conditions favorable to differentiation [25,26,27]. 
These chromatin regulators include histone-modifying enzymes, ATP-
dependent nucleosome remodeling complexes, DNA (de)methylation 
complexes and higher order chromatin organizers, such as CTCF and cohesion 
[4,28]. 
 
1.1.3.1 Histone-modifying enzymes 
 Tails emanating from histone proteins in the nucleosomes are subjected 
to certain reversible post-translational modifications (PTMs) such as 
methylation, acetylation, phosphorylation and ubiquitination [29,30]. 
Combinations of the histone PTMs influence numerous molecular processes; 
therefore, complexes that are “reading”, ”writing” and “erasing” certain 
modifications have significant roles in ESC biology [31,32,33].  
 One of the key features of ESCs is the presence of bivalent histone 
modifications at the regulatory sites of certain genes [34]. Genes encoding 
developmental and lineage-specific regulators are held in a “poised” state by 
bivalent histone modifications, defined as concomitant active histone mark 
histone H3 lysine 4 tri-methylation (H3K4me3) and repressive histone mark 
histone H3 lysine 27 tri-methylation (H3K27me3) on the same chromatin region. 
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These poised genes are silent in pluripotent cells but rapidly activated in 
response to signals that induce differentiation by changing the histone PTM 
status near promoters [35,36,37,38]. In general, Trithorax group (TrxG) proteins 
deposit H3K4me3 marks at promoters, and promote the transcription of active 
genes [39]. On the other hand, polycomb group (PcG) proteins catalyze 
deposition of H3K27me3 and, when present as a bivalent PTM prevent the 
transcription of developmental or key signaling genes in order to maintain a 
pluripotent state [40,41,42].  Several studies have shown that depletion of 
certain TrxG complex proteins or subunits of the PcG complex, such as PRC1 
and PRC2, leads to defects in pluripotency maintenance and proper 
differentiation, supporting their importance in ESCs [43,44,45]. Genome-wide 
mapping comparisons revealed high co-localization of core pluripotency factors 
with PcG proteins [17,42]; moreover, Oct4 is reported to interact with 
components of TrxG and PcG complexes [46]. Taken together, these findings 
suggest an interconnection between core transcription factors and histone-
modifying enzymes in order to maintain pluripotency. As ESCs differentiate into 
a certain lineage, specific developmental factors are induced by mechanisms 
that retain the active histone mark (H3K4me3) while removing the repressive 
histone mark (H3K27me3). In parallel, non-induced genes, such as regulators 
of cellular lineages that are not induced, tend to lose their “poising”, active 
histone modifications and acquire more H3K27me3 mark, which provides a 
mechanism for how bivalent domains help to establish ESC plasticity [38,47] 
(Figure1). 
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 In addition to H3K27me3, histone H3 lysine 9 tri-methylation (H3K9me3) 
is another important repressive histone modification for ESCs [48]. SetDb1, 
G9a and Suv39h1 are involved in catalysis of H3K9me3, which has been 
shown to repress diverse developmental regulators in the pluripotent state 
[49,50,51]. Thus, various histone modifiers are involved in gene silencing of 
several developmental regulators in ESCs. 
  Histone acetyltransferases (HATs) are also implicated in the regulation of 
pluripotency and lineage-specific differentiation. The Tip60-p400 complex, 
which catalyzes histone H4 acetylation, also targets most of the Nanog binding 
sites and based on functional screens emerged as an ESC identifier [52]. 
Another HAT, p300, together with the presence of the histone H3 lysine 4 
mono-methylation (H3K4me1) mark, has been associated with enhancer 
regions and co-localizes significantly with key transcription factors at promoter 
distal regions of genes in ESCs [53]. Similar to ESC promoters, enhancers may 
also exist in poised (marked with H3K27me3) or active states (marked with 
H3K27ac) [54,55]. Although the mechanism remains elusive, during 
differentiation poised enhancers are converted to active ones, a process that 
requires HAT enzyme activity to deposit acetylation on histone H3 lysine 27 in a 
lineage-specific manner, and consequently help to establish tissue-specific 
gene expression programs [56,57,58].  
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Figure 1. Bivalent chromatin domains help to establish embryonic stem 
cell plasticity. Reprinted by permission from Elsevier: Current Opinion in 
Genetics & Development, copyright (2008) [31]. 
Promoter of developmental transcription factor, Otx2 (neural-specific 
developmental factor) is marked by bivalent chromatin marks (H3K4me3 and 
H3K27me3) and transcriptionally poised in ES cells. In neural progenitor cells, 
Otx2 is transcribed and promoter is only associated with activating mark 
H4K3me3 while repressive histone mark H3K27me3 is selectively removed. In 
embryonic fibroblast cells, the expression of Otx2 is permanently repressed as 
a result of remaining H3K27me3 mark. 
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1.1.4 Non-coding RNAs 
A number of genome-wide transcription studies inferred that the majority 
of the mammalian genome is transcribed, and many of these transcribed 
regions do not encode for a protein [59]. Subsequent studies revealed some of 
the biological functions of these pervasive non-coding transcripts [60]. 
Regulatory roles of non-coding RNAs (ncRNAs) in bio-molecular processes 
include repeated elements silencing, X-chromosome inactivation, polycomb 
repression and regulation of embryogenesis at different stages [61]. A diverse 
group of ncRNAs transcripts have been postulated to control, in part, the ESC 
state, including microRNAs (miRNAs) and large intergenic ncRNAs (lncRNAs) 
[62]. 
miRNAs are small ncRNAs (~22 nucleotide long) that are involved in 
post-translational mRNA silencing by base pairing to complementary 
sequences of their target RNAs in order to regulate a gene-expression program 
in cells [63,64]. Lack of miRNA biogenesis pathway components (Dicer and 
DGCR8) in mouse ESC results in defects in differentiation and decreased 
proliferation rates, which demonstrates the importance of this particular ncRNA 
family for the regulatory circuitry of pluripotent state [65,66]. Two key themes 
emerged from a study by Marson et al., which revealed how miRNAs integrate 
into that regulatory circuitry[67]: 
1) Key transcription factors induce expression of miRNAs that are critical 
to fine-tune the mRNA levels of ESC-related genes that maintain pluripotency 
and those that facilitate the rapid degradation of ESC transcripts during 
differentiation and establish cell state transitions [68,69]. The cluster of mir-290-
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295 constitutes a big portion of such miRNAs [70]. Members of this cluster 
contain seed sequences that can recognize mRNA of proliferation-related or 
epigenetic modulator genes; and, therefore, are involved in maintenance of 
pluripotency. 
2) In the same fashion as lineage-dependent gene regulation, with the 
help of repressive chromatin regulators SetDB1 and PcG complexes, key 
transcription factors poise the expression of certain miRNA families. These 
miRNAs are up-regulated during lineage-programming and inhibit several key 
genes that are required to maintain pluripotency [71]. For example, human miR-
145 can target and repress pluripotency specific genes, including OCT4, SOX2, 
and KLF4. OCT4 binds to up-stream regions of the miR-145 promoter and 
poises its expression in hESCs to establish an “irreversible positive feedback” 
loop that helps to control the balance between pluripotency and differentiation 
[72]. 
Discovered lnRNAs are defined as intergenic transcripts longer than 200 
nucleotides in length with little potential for coding functional proteins and 
revealed by a specific chromatin signature: a combination of promoter-
associated H3K4me3 and RNA Polymerase II (PolII) elongation mark histone 
H3 lysine 36 tri-methylation (H3K36me3) [73,74]. They can play important roles 
in numerous cellular processes, including participation in a pluripotency-
differentiation balance with some lncRNAs favoring pluripotency and others 
differentiation [75,76]. An intriguing study by Guttman et al. revealed that, 
majority of lncRNA regulatory regions are bound by core transcription factors in 
ESCs [77]. This suggests that, like protein coding genes, lncRNAs are also 
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regulated by core pluripotency factors to maintain the ES cell state. Additionally, 
in the same study, the functional relevance of 226 lncRNAs were assessed by 
RNA interference experiments in mouse ESCs and supported a model where 
impairment of lnRNA expression influences proper ESC maintenance as well as 
differentiation. Intriguingly, RNA immunoprecipitation experiments indicated that 
~75% of lincRNAs were bound to at least one chromatin regulatory complex, 
such as PcG and/or LSD1-histone demethylase proteins, substantiating the 
hypothesis that lncRNAs may function as modular scaffolds to bring different 
proteins or complexes together and reinforce the recruitment and stabilization of 
chromatin complexes during development and pluripotency [78,79,80]. 
 
1.1.5 Signaling mediators of the ESC state 
Signal-transduction pathways are involved in regulation of various 
cellular processes, and perturbations in a signaling cascade may lead to severe 
abnormalities, including initiation or progression of cancer [81].   As a part of an 
effort towards deconstructing regulatory mechanisms of ESCs and development, 
numerous signaling pathways were scrutinized in detail and divided into intrinsic 
ones, which maintain an ESC state, and extrinsic signaling, which initiates 
lineage-specific differentiation [22,82,83]. 
 
1.1.5.1 Signaling pathways that maintain pluripotency 
Extrinsic signaling pathways that impinge on pluripotency are distinct in 
human ESCs from those in mouse ESCs [84,85]. LIF and BMP pathways are 
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related to sustain mouse ESC state; whereas, transforming growth factor-β 
(TGF-β) signaling is one of the key pathways that maintain pluripotency in 
hESCs [86]. Activin and nodal proteins are members of the TGF-β family of 
ligands and suppress hESC differentiation, in part, by blocking BMP4 
expression [87]. Additionally, Activin/nodal proteins can activate effector 
transcription factors (SMAD2/3), which in conjunction with an extracellular 
protein FGF2, up-regulate expression of core transcription factors NANOG and 
OCT4 to support hESC self-renewal [88,89,90]. Even though, WNT-mediated 
signaling has been implied in short-term pluripotency maintenance, the 
underlying mechanisms remain uncertain [91]. In summary, several 
extracellular signaling pathways play critical roles in the regulation and 
maintenance of ESC state. 
 
1.1.5.2 Differentiation-related extrinsic signaling pathways 
Pluripotent ES cell can give rise to three primary germ layers: endoderm 
(pancreas, lung, gut), ectoderm (nerve, skin) and mesoderm (muscle, blood), 
which are initiated by different extrinsic signaling pathways. Specific small 
molecules and receptor ligands either alone or in combination cocktails are 
used to differentiate ESCs into a specific lineage. In this study, we utilized 
Retinoic Acid (RA) signaling pathway as a model system to study early lineage-
specific (neuro-ectoderm in particular) differentiation of hESCs. 
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1.1.5.2.1 Retinoic Acid signaling 
Active metabolites of Vitamin A are collectively called retinoids, and they 
have been implicated in regulation of various biological processes [92]. For 
animals, dietary intake is the only source of retinoids since de novo synthesis 
mechanisms for these molecules do not exist. Several enzymes are involved in 
retinoid uptake regulation in mammalian systems. Retinoids are first converted 
into retinaldehyde by oxidization enzymes called alcohol dehydrogenases 
(ADHs). Retinaldehyde dehydrogenase (RALDHs) enzymes catalyze the 
second step (oxidization of retinaldehyde), from which Retinoic Acids (RAs) are 
produced [93]. RALDH2 is the sole enzyme responsible for embryonic uptake of 
RAs that, when deleted in mice, results in lethality, which signifies the 
importance of RAs during mammalian embryogenesis [94]. Given their 
significance in development, distribution patterns of RAs are strictly controlled 
by cytochrome P450 26 subfamily proteins that convert RA into less stable 
byproducts which are rapidly degraded in tissues that should not receive RA 
signaling [95]. 
Once transported inside the cell, RAs are shuttled to the nucleus with the 
help of specialized-proteins, such as CRABP2 (cellular RA-binding proteins). In 
the nucleus, RAs form a new complex by binding to retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs), which when activated by RA-binding 
form heterodimers and bind to specific DNA motifs known as RA-response 
elements (RAREs). Following DNA binding of the RXR/RAR complex, a number 
of co-activators, e.g. NF1, together with ATP-dependent chromatin remodeling 
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complexes are recruited to RAREs in order to facilitate transcription of lineage-
specific RA-responsive genes [96].  
Early studies demonstrated that RA-treated ESCs undergo neuro-
ectodermal lineage differentiation, which leads to the formation of neural 
progenitor cells [97]. Numerous RA target genes have been identified so far, 
including developmental transcription factor HoxA1, suggesting that activation 
of RA signaling drives ESCs towards neural-lineage development by inducing 
expression of a particular set of lineage-specific developmental factors [93,98]. 
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1.1.6 Induced Pluripotent Stem Cells 
A groundbreaking experiment in 2006 performed by Yamanaka’s lab – 
for which Dr. Yamanaka eventually was awarded the 2012 Nobel Prize in 
Physiology or Medicine - demonstrated that retroviral-mediated transfer of four 
transcription factors (Oct4, Sox2, Klf4 and c-Myc) can reprogram differentiated 
mouse embryonic fibroblasts to an ESC-like state, known as induced pluripotent 
stem cells (iPSCs) [99]. Successive studies showed that similar reprogramming 
could be achieved by the transduction of the same or a modified set, e.g. Lin28 
as substitute for Klf4 and c-Myc as a dispensable factor, of transcription factors 
in human differentiated cells [100,101,102].  Similarly, some ncRNAs, such as 
lincRNA-regulator of programming (linc-RoR) [103], or miRNAs, miR-294 and 
miR-295 [104], can also be used to enhance reprogramming efficiencies. 
Notably, in vivo studies elucidated the striking morphological and 
biological similarities between ESCs and iPSCs, including the most stringent 
tests of pluripotency: differentiation into multiple germ layers and formation of 
teratomas [99]. Comparison of the genome-wide binding of core transcriptional 
factors demonstrated that localization of these factors significantly overlaps 
between hESCs and hiPSCs, except at some heterochromatin regions marked 
by H3K9me3 (named as OSKM-DBRs) [105,106]. Although some studies 
indicate that reprogramming fails to completely erase the epigenetic memory of 
the cell of origin [106], limited but consistent genome-wide transcriptional and 
chromatin-based variations, mainly bivalent modifications, H3K4me3 and 
H3K27me3, are observed between hESCs and hiPSCs [107] (Figure2). Taken 
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together, shared similarities by ES and iPS cells increase the hopes that human 
iPS cells could one day be used as therapeutic agents in immune-matched 
patient-specific regenerative medicine practices [108]. 
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Figure 2. Genome-wide bivalent chromatin modification maps show 
significant similarities between human iPS and ES cells. Reprinted by 
permission from Elsevier: Cell Stem Cell, copyright (2010) [107].  
 
A. Aggregate plot show H3K4me3 enrichment profile for all RefSeq genes in ES 
cells (solid blue) and iPS cells (dashed blue). The arrow indicates transcription 
start site (TSS) and direction of transcription of the average. 
 
B. Heatmap depicts the density of H3K4me3 mark (blue) around all Refseq 
genes promoters – genomic region from -4.5kb to +4.5kb relative to the TSS is 
shown. Gene order was determined by highest average ChIP-Seq density in ES 
cells and arranged from highest to lowest density.  
 
C. Aggregate plot show H3K4me3 enrichment profile for all RefSeq genes in ES 
cells (solid blue) and iPS cells (dashed blue). 
 
D. Heatmap depicts the density of H3K27me3 mark (green) around all Refseq 
genes promoters – genomic region from -4.5kb to +4.5kb relative to the TSS is 
shown.  
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1.1.7 ESC-specific gene expression signatures in human cancer 
Cancer cells exhibit molecular and biological traits that resemble some 
hallmarks of stem cells, including high proliferation rate, self-renewal and even 
lack of differentiation since some aggressive tumors are present in an 
undifferentiated state [109]. Recent studies showed that ES cell-like gene 
expression signatures are shared among different human cancers, which could 
account for some of the reported similarities between cancer and ES cells [110].  
One of the earliest studies that compared the underlying gene expression 
programs of ESCs and epithelial cancer cells revealed an evolutionary 
conserved (between mouse and man) ESC-like transcriptional signature, which 
is activated in various human epithelial cancers yet suppressed in normal cells 
[111]. Furthermore, Weinberg and colleagues have shown that poorly 
differentiated human tumors exhibit transcription of ES-cell-specific genes along 
with repression of PcG complex (PRC2, Eed and Suz12) target genes [112] 
(Figure3). In contrast, a more recent study argued that recapitulated ESC-like 
gene expression signatures in cancers are mainly due to activation of pro-
proliferation factor c-Myc in human tumors but not the core transcription factors 
[113]. Although, the idea is compelling, since c-Myc locus amplification is one of 
the most frequent copy-number alterations in human cancers [114], it is unclear 
how c-Myc can be solely responsible for the activation of a core ESC program 
during tumor initiation, considering that c-Myc is not strictly required for iPS cell 
generation or reprogramming [102]. Overall, accumulated evidence indicates 
that an ES cell-like gene expression program is positively correlated with poorly 
differentiated tumors (histologically graded), increased risk of metastasis and 
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decreased survival rate in human patients. 
 
 
 
 
 
 
Figure 3. High-grade human breast cancers display ES-cell-specific gene 
expression signature. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Genetics, copyright (2008) [112].  
1,211 breast cancer samples have been investigated (columns). Red/green 
colors indicate significantly over- or under expressed gene sets, respectively. 
Bottom bars (brown) indicate individual tumor annotations  - where available - 
for ER status (positive or negative), grade (1,2 or 3), and tumor size (S – tumor 
smaller than 2cm, L – tumor larger than 2cm). 
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1.2 p53 and Pluripotency 
 Transcription factor p53 drives expression of an array of target genes in a 
cellular-context and stress-stimuli specific manner. p53’s function as a tumor 
suppressor has long been recognized, hence it is aptly named as the “guardian 
of the genome”. It functions as a tumor suppressor by promoting apoptosis and 
regulating cell proliferation, primarily by cell-cycle arrest, in response to various 
stress signals, such as oncogenic activation, tumor-suppressor gene 
inactivation, genotoxic damage exposure and loss of normal cell-cell contacts. 
Thus, p53 prevents an accumulation of genomic instability, which is one of the 
major causes of cancer formation [115]. However, p53’s contribution to 
numerous other cellular processes has only recently been appreciated, 
including its functions in development and differentiation [116]. 
 
1.2.1 p53 acts as barrier to somatic cell reprogramming 
The seminal study by Takahashi and Yamanaka on nuclear 
reprogramming offers great possibilities for regenerative medicine, as 
generation of patient-specific iPS cells becomes feasible, in addition to the 
ability to study mechanisms of development and disease in these cell systems. 
However, the shortcomings of the original method, namely, an inefficient 
reprogramming rate (1-3%) and slow kinetics of iPSC generation (as long as 
several weeks), are major drawbacks to the clinical use of reprogrammed cells. 
These challenges led researchers to consider whether proteins that acted as 
barriers and limited somatic cell reprogramming were expressed in 
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differentiated cells. 
Notably, five simultaneous reports showed, by various experimental 
approaches, that depleting p53 or inhibiting p53-dependet pathways to disrupt 
p53 functions dramatically increases the reprogramming rate (as much as 
80%) and accelerates the kinetics (as early as 3 to 5 days) of iPSCs 
generation [117,118,119,120,121]. Although the obtained results were exciting 
and encouraging, several concerns have arisen regarding inhibition of a crucial 
tumor suppressor during reprogramming [122,123].  One of the previously 
mentioned five studies, Hong et al., observed that mice generated by partially 
using p53-deficient iPS cells were viable but these mice eventually developed 
tumors [117]. In addition, Marion et al. reported increased genome instability 
and abnormal telomere shortening in p53-deficient iPS cells [120]. Although, 
the use of oncogenic reprogramming factors, such as c-Myc and Klf4 or 
retroviral-mediated infections may be potential explanations for the induction of 
p53 and its activity as a barrier to reprogramming, less oncogenic 
reprogramming techniques, which exclude oncogenic factors from the 
reprogramming cocktail or using different transfection methods, still lead to a 
p53-mediated cell-cycle arrest of a majority of cells during reprogramming. This 
suggests that p53’s function during creation of iPS cells could extend beyond 
its responsibility to safeguard the genomic integrity during oncogenic stress 
[124].  
 
1.2.2 p53-inactivated cancers display plasticity and loss of differentiation 
Although cancerous cells exhibit striking differences between individuals 
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or due to the tissue origin of the disease, most of them share one general 
deficiency: p53 loss-of-function, which underscores the importance of p53 in 
maintaining cellular integrity. Given p53’s prominent role to restrain cellular 
reprogramming and the gene expression signatures shared between cancers 
and ES cells, it is reasonable to ask whether there is a positive correlation 
between p53 inactivation and acquisition of a stem-like state.  
In two separate studies, Levine and associates surveyed global gene 
expression in metastatic breast and lung cancers [125], or prostate tumors 
[126], and demonstrated that cancers that are mutant for p53 function exhibit 
an ESC-like expression program that correlated with worse overall survival 
rates for patients. A similar association was previously observed at a molecular 
level in poorly differentiated thyroid cancers [127], in lung cancers [128] or in 
acute myeloid leukemia progenitors [129]. Consistent with these findings, it has 
also been shown that expression of p53 induces differentiation of leukemia-
derived cells K562 cells [130].  
Taken together, a better understanding regarding the pathways that drive 
dedifferentiation in p53-inactivated cells or the precise mechanism of how p53 
can function to favor differentiation is required to enhance efficiency of iPS cell 
production without jeopardizing genomic stability of those cells. Additionally, a 
better understanding of how tumor cells acquire cellular plasticity after p53-
inactivation may lead to development of more potent and targeted therapeutic 
treatments.   
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1.2.3 p53’s function in human ES cell differentiation 
Tumor suppressor p53 has been implicated in limiting the self-renewal of 
stem cells, specifically in mouse ES cells by suppressing core pluripotency 
factor Nanog [131] or by activating developmental Wnt-signaling [132]. These 
findings led to the hypothesis that p53 imposes differentiation of mouse ESC 
as a tumor-suppressive mechanism in response to DNA damage [133]. In 
addition to being regulated by distinct extrinsic signaling pathways, multiple 
studies suggest there are fundamental differences between mouse and human 
ES cells at the basic mechanisms of transcription factor function. As an 
example, even the core transcription factor binding sites show significant 
differences: only 5% of the most enriched OCT4 and NANOG binding sites in 
hESC are present at homologous regions in mice [134,135]. Additionally, 
hESCs contain one inactivated X-chromosome thereby present in a “primed” 
state for differentiation, while mESCs are in a more primitive, “naïve” state, 
which maintain two active X-chromosomes [136,137]. Further understanding of 
the earliest stages of human embryonic development is needed to resolve 
such controversies [138].  
Unlike differentiation in mouse ES cells, p53-dependent cell cycle arrest 
is observed in human ES cells in response to DNA-damage [139], which 
suggests that different stress-specific functions of p53 exist between mouse 
and man. Recent work from our laboratory revealed that p53 plays a significant 
role during retinoic acid-mediated differentiation of human ESCs. Depletion of 
p53 results in inefficiencies during differentiation since the majority of the cells 
maintain higher levels of OCT4 and NANOG expression even after several 
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days of RA treatment. This suggests that p53 is an important factor for efficient 
differentiation of hESCs [140]. Human ESCs stably expressing wild-type p53 
under TET-inducible promoter underwent differentiation even in absence of 
Retinoic Acid. However, the same effect was not observed when a mutated 
form of p53, p53R175H, which is incapable of binding to DNA, is ectopically 
expressed. This suggests that p53 promotes hESC differentiation by binding to 
DNA and functioning as a transcription factor to activate or repress targets 
gene expression.  
 Further analyses revealed that, in response to RA, p53 is enriched at 
the promoter of one of the key p53-effector genes, p21 or CDKN1A and 
induces its expression. This is significant since higher levels of p21 results in 
the accumulation of hESCs in G1-phase of cell cycle, which promotes 
differentiation. These actions of p53 in hESCs are in complete contrast to its 
roles in mouse ESC differentiation, where it represses Nanog expression by 
directly binding to its promoter [131]. Lengthening of the hES cell cycle and 
impeding rapid cell divisions not only limit self-renewal but also facilitate the 
programs that induce differentiation [141]. Additionally, p53 also activates 
expression of specific micro-RNAs, miR-145 and miR-34a, which repress 
expression levels of core pluripotency factors OCT4, SOX2 and KLF4 and thus 
prevent partially differentiated hESCs from backsliding to pluripotency.  
 
1.3 Genome-wide protein-chromatin interaction studies 
 Cell fate and development are established through an intricate network 
that regulates gene expression programs in a certain tissue at a given time. 
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Understanding the nature of DNA-protein interactions and epigenetic 
modifications is crucial for deciphering the codes of the underlying gene 
regulatory networks [5]. Several approaches have been devised to identify 
genome-wide locations of transcription factor binding and histone modifications 
[142]. Chromatin immunoprecipitation (ChIP) is a powerful method to purify 
DNA fragments that are associated with a particular transcription factor (TF) or 
a post-transcriptionally modified histone. Initial high-throughput screens used 
ChIP and predesigned microarrays, a method known as ChIP-chip, by 
hybridizing fluorescent-labeled, ChIP-antibody precipitated fragments of DNA to 
homologous oligomers of DNA fixed to substrates [143]. Although, whole 
genome tiling arrays can be used to screen entire genome in a ChIP-chip study, 
this method requires several chips per condition, therefore is infeasible and not 
cost-effective for mammalian genome studies [144]. 
 Advancements in next-generation sequencing technology, where the 
antibody-bound chromatin fragments obtained from a ChIP experiment are 
directly subjected to deep sequencing of DNA, made identification of DNA-
protein interactions more comprehensive [145]. Chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) is advantageous over the ChIP-chip method 
in several ways: it provides better resolution and unbiased genome coverage, 
obtained results contain fewer artifacts and it requires smaller amounts of 
starting material [146,147]. Numerous computational tools have been 
developed to pinpoint the precise location of a protein of interest’s binding site 
within the genome of the studied organism and to annotate or compare the 
obtained data for downstream analyses [147].  
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 Some common steps of ChIP-Seq data analysis pipeline can be listed as: 
 Read mapping – As a first step, obtained sequenced ChIP fragments (tags) 
are aligned onto the genome with the help of any available short-read 
mappers (i.e. Bowtie, BWA or Illumina’s ELAND software). 
 Identification of significantly enriched regions (Peak calling) – Once 
alignment is done, the next step is to identify genomic sites where the 
obtained reads are enriched significantly higher than expected by chance. 
Although ChIP-seq offers less technical artifacts, it is still subject to some 
inherent biases due to the experimental protocols (antibody specificity), 
sequencing technology (non-specific noise) or the genomic structure 
(regional GC bias, open chromatin regions tend to precipitate more easily). 
Thus generating input control data is a vital step for augmenting this 
identification step.  
 Down-stream analysis – Several subsequent analyses can be performed 
based on the purpose of the study, such as identifying location of the 
enriched regions on the genome relative to any known genomic features, 
motif discovery or incorporating gene expression data to identify potential 
function of studied transcription factor.  
 
1.4 Hypothesis, specific aims and rationale 
My hypothesis is that p53 regulates transcription of a signal-specific subset of 
genomic targets in hESCs that a) oppose pluripotency and b) protect the stem 
cell genome in response to differentiation and DNA damage. 
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Specific Aims 
I tested this hypothesis by the following specific aims: 
Specific Aim 1) To characterize p53’s genome-wide binding profiles in 
DNA-damaged induced hESCs. 
Specific Aim 2) To characterize p53’s genome-wide binding profiles in 
differentiating hESCs and their potential functions. 
Specific Aim 3) To compare p53-enriched sites with ES cell landmark 
signatures. 
 
Rationale: p53 protein levels are elevated to comparable levels in DNA 
damage-induced hESCs and differentiation-initiated hESCs. Although similar 
abundance of p53 is observed under these conditions, cellular outcomes are 
strikingly different where DNA damage causes cells to arrest or undergo 
apoptosis and RA induces cells to differentiate and change their molecular 
signature. Our previous data showed that p53’s DNA-binding ability is essential 
for its role of promoting hESCs differentiation. Thereby, p53’s binding 
preferences could be the dictating factor for the different readouts and 
identification of those p53 binding sites may reveal which subset of target genes 
are responsible for each specific response.  
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CHAPTER 2 MATERIAL AND METHODS 
2.1 ChIP-Seq Analysis 
2.1.1  Sequencing and read alignment 
Sequencing of p53-bound DNA was performed at the Bioinformatics 
Core of the Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. p53-
bound DNA (~10 ng) was purified by PAGE to obtain 100–300 bp fragments 
and sequenced on an Illumina Solexa GAII sequencer. Sequencing of 
chromatin marks H3K4me3 and H3K27me3 ChIP DNA was performed at the 
MD Anderson DNA Analysis Facility. DNA associated with modified histones 
(~10 ng) was purified by PAGE to obtain 100–300 bp fragments and sequenced 
on an Illumina HiSeq2000 sequencer. Sequence reads (36 base pair long) 
derived from Illumina sequencers were aligned to the NCBI Build 36 (UCSC 
hg18) human genome using ELAND software (Illumina) to produce uniquely 
matched reads with up to two mismatches per read allowance. 
2.1.2  Peak calling 
 Enriched regions for each condition were normalized to input DNA and 
detected by MACS version 1.4.0 (Model based analysis of ChIP, 
http://liulab.dfci.harvard.edu/MACS/) [148] with a p-value threshold of 
enrichment of P < 1.00 E-8 for damage and differentiation datasets; however, a 
higher cut-off was used for untreated dataset because of the low throughput 
and high signal-to-noise ratio in this experiment - P < 1.00 E-10. Non-default 
shift and bandwidth sizes were used for each dataset based on average 
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precipitated DNA fragments length in each case. Wiggle files 
(http://genome.ucsc.edu/goldenPath/help/wiggle.html) were generated using 
the same sequence files and density of reads per base pair was calculated in a 
25bp window and later normalized to 10 million reads per sample.  
 Peaks share at least one base under their enriched regions called as 
overlapped between different conditions. BEDTools functions (intersectBed or 
windowBed) were used to perform overlapping sites analyses 
(http://code.google.com/p/bedtools/) [149].  
 The distance between unique peaks in each condition was measured 
using a gradually increasing window and determining the unique peaks summits 
coinciding in the same window. Obtained numbers were plotted and pie charts 
were generated by ratios of overlapping versus non-overlapping summits for a 
certain window length.  
 
2.1.3   Conservation of binding sites 
 PhastCons conservation scores for 44 vertebrate species were 
downloaded from UCSC website (which contains base-by-base conservation 
scores based on a statistical model called phylogenetic hidden Markov model 
[150]) and individual chromosome files were merged into a single wiggle file 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/phastCons44way/vertebrate/
). Aggregate plots for conservation scores across (-3kb to +3kb) enriched sites 
were generated using the Sitepro version 0.6.6 program under CEAS 
(http://liulab.dfci.harvard.edu/CEAS/) [151] with 100bp resolution. 
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2.1.4   Motif analysis 
 Both de-novo motif discovery and known motif matching were performed 
using the MEME software suit. The sequences of the p53-peak regions were 
extracted in FASTA format and used as input for the MEME-ChIP pipeline, 
which is specifically designed to discover associated motifs in large sets of DNA 
sequences (http://meme.nbcr.net/meme4_6_1/memechip-intro.html) [152]. The 
pipeline runs MEME (good for long motifs) [153], DREME (good for short 
motifs) [154] for over-represented DNA-sequences in input, and AME (Analysis 
of motif enrichment) to search and compare the motifs that are discovered by 
MEME and DREME in the existing motif databases [155]. Briefly, zero or one 
motif per sequence was searched with the motif lengths between 6-30 base 
pairs, around 600bp of the peak summits and outputs for each dataset are 
shown with a p-value cut-off less than 1.00 E-10. 
 SeqPos motif discovery program in Cistrome analysis pipeline 
(http://cistrome.org/ap/) [156] was also performed for motif discovery 
underneath enriched sites (around 400bp of the peak’s center) in each 
condition by using cistrome’s curated motif database.  
 
2.1.5  Identifying target genes of p53-bound sites 
 Human RefSeq gene information was obtained from UCSC table browser 
for human genome hg18 assembly (http://genome.ucsc.edu/cgi-
bin/hgTables?command=start) [157]. Fold enrichment analysis over the 
randomized binding sites was performed as previously described [158]. Genes 
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with a nearby p53 peak 10Kb up/down-stream of transcription start sites were 
designated as targets.  
 
2.1.6  Annotation of p53-target genes 
 Gene Ontology analyses for each set of target genes were performed 
using DAVID (http://david.abcc.ncifcrf.gov/) [159]. Developmental transcription 
factors were obtained from the HUGO Gene Nomenclature Committee at the 
European Bioinformatics Institute’s website 
(http://www.genenames.org/genefamily.html) [160], previously published study 
annotations (Supplementary table S11 in Lee et al. 
http://www.sciencedirect.com/science/article/pii/S0092867406003849#mmc12) 
[17] and NCBI’s Gene database (http://www.ncbi.nlm.nih.gov/gene). Each dot 
shown represents a member of a particular family only if the gene’s ontology 
terms (GO - Biological Process and Molecular Function) entail transcription or 
DNA binding and also development or differentiation. Gephi (http://gephi.org/) 
graphic visualization software was used to generate network graph. 
 INTERPRO protein domain analysis was performed using Genomic 
Regions Enrichment of Annotations Tool or GREAT (great.stanford.edu) [161]. 
Peak files (Differentiation-specific, Damage-specific and conserved p53 
bindings sites) were imported into GREAT by setting a gene association rule as 
a single gene within 10 kb ranges of binding sites. The top five categories by 
binomial p-value scores are shown.  
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2.1.7  Integration core ES cell transcription factor binding data 
 ChIP-Seq datasets of OCT4 (GSM518373) and NANOG (GSM518374) 
were obtained from GEO database (http://www.ncbi.nlm.nih.gov/geo/) [162]. 
Raw sequences were re-analyzed with MACS version 1.4.0. Obtained peaks 
were used for overlap analysis and circular plot. Circos (http://circos.ca/) [163] 
was used to visualize p53, OCT4, NANOG and H3K27me3 around four HOX 
clusters. H3K27me3 ChIP-Seq data was obtained from UCSC genome 
browsers’ ENCODE project website 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC/wgEncodeBroa
dChipSeq/) [164].  
 Wiggle files were generated by using the obtained sequence files and 
density of reads per base pair was calculated in a 25bp window and later 
normalized to 10 million reads per sample and used for aggregate plots which 
were generated by using Sitepro program in CEAS toolkit. Normalized wiggle 
files were used to generate a density plot, using the heatmap tool in the 
Cistrome analysis pipeline (http://cistrome.org/ap/) [165]. K-means clustering (5 
cluster) was applied to the intensity signals of p53-Damage, p53-Differentiation, 
OCT4 and NANOG that were extracted around (-500 to +500bp) the p53-
condition-specific genomic regions.  
 Peaks share at least one base under their enriched regions called as 
overlapped between different datasets (OCT4, NANOG, p53-Damage, p53-
Differentiation). BEDTools functions (intersectBed or windowBed) were used to 
perform overlapping sites analyses (http://code.google.com/p/bedtools/). 
 In order to test if observed differences in the association of OCT4 and 
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NANOG with p53-Differentiation is significant, randomized binding sites 
showing similar distribution in each chromosome were generated 10000 times 
and used for determining statistical significance.  
 
2.1.8  Bivalent histone modification analysis 
 Normalized wiggle files were used to generate histone aggregate plots. 
Transcription start site (TSS) of p53 target genes (up or down-regulated based 
on microarray data results) was used as the center of the window and each 
window was divided into 40 bins of 25bp resolution. Average ratios were plotted 
for each category. 
 
2.2 Gene Expression Analysis 
Affymetrix U133 Plus2.0 microarrays were performed for each condition 
(Pluripotent, +Adr and +RA) in triplicates. Robust multi-array average (RMA) 
method was used with default options (with background correction, quantile 
normalization, and log transformation) to normalize raw data from batches using 
R/Bioconductor‘s affy package (http://www.bioconductor.org/) [166]. 
EntrezGene IDs were assigned to the probe-sets using Affymetrix annotation 
package (hgu133plus2.db) in Bioconductor. For genes, which are represented 
by multiple probes on the array, maximum expression value was retained for 
further analyses. A gene is called as differentially expressed if FDR corrected p-
value is less than 0.05, which is calculated with empirical Bayes method by 
eBayes function in Bioconductor’s limma package [167]. Gene Ontology 
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analysis of differentially expressed gene was performed using DAVID 
(http://david.abcc.ncifcrf.gov/). Volcano plot is generated by using R’s plot 
function, whereas the bar plots were generated by using ggplot2 
(http://ggplot2.org/) package. 
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CHAPTER 3 RESULTS 
3.1 Genome wide mapping of p53 in hESCs reveal distinct 
functional binding sites  
 We mapped p53 occupancy throughout the genome using ChIP-Seq 
method by deep sequencing of p53-bound chromatin fragments isolated from 
hESCs in a pluripotent state (untreated), undergoing differentiation (+RA) or 
after DNA damage (+Adr) in order to determine the molecular basis for these 
signal-specific responses and define a landscape of p53-chromatin interactions 
in hESCs. In pluripotent hESCs, p53 is enriched at 4509 genomic sites, 
compared to 8282 and 4941 in hESCs undergoing differentiation or damage, 
respectively (Figure 4). We found that p53 is enriched at distinct loci during 
each of these different conditions, since intersection of obtained enriched sites 
demonstrated that only a fraction of p53-bound peaks (26.5%) overlapped in 
between differentiation and damage induction (Figure 4). Comparison of unique 
sites in a gradually increasing genomic window revealed that only 44% of 
unique sites in differentiation and damage overlapped in a 100kb window, 
suggesting highly diverse p53 functions in these two states (Figure 5).  
 We investigated the evolutionary importance of identified p53-binding sites 
by profiling PhastCons score around those sites. Comparing genomic regions 
within 4kb of each p53-peak summit in 44 vertebrate species, revealed high 
evolutionary conservation of p53 binding regions suggesting potential regulatory 
functions of obtained genomic regions in each condition (Figure 6).  
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Figure 4. Genome-wide mapping demonstrated unique p53 signatures in 
hESCs after different treatments 
 
Comparison of genome occupancy of p53 in untreated, differentiation (RA 
2days) and damage (Adriamycin: Adr 6h) induced hESCs. p53 binding sites 
identified by peak calling program MACS with p-value 10-8.  
Differentiation Damage
Untreated
5550
1639
3324
536
557
92
2653
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Figure 5. Condition specific binding sites of p53 are strikingly distant 
 
Frequency of overlap between unique sites is shown as a function of distance 
between binding sites. Pie charts show percent overlap between unique sites in 
100kb distance. Poor overlap of unique sites in differentiation and damage was 
observed (44%) even in a 100kb window.   
54%
46%
69%
31%
44%
56%
 Figure 6. p53 binding regions are evolutionary conserved among 
vertebrates. 
 
Average PhastCons score profiles depicting conservation in the vicinity of p53 
binding sites and randomly generated genomic loci (purple). 
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3.2 p53 binding sites are enriched for p53 and OCT4:SOX motifs in 
differentiation 
 Motif analysis revealed that p53-bound regions were significantly enriched 
with consensus p53 binding sites (p53-motif) in both differentiation and damage 
(P < 10-35 and P < 10-235, respectively), a motif that is similar to the p53 
consensus obtained from TRANSFAC database (Figure 7A). However, 
sequences bound by p53 in pluripotent hESCs (untreated) did not match the 
consensus p53-motif significantly (P > 10-5), suggesting signals that activate 
p53 in hESCs stabilize p53-chromatin interactions, as a result precipitating 
precise p53-bound regions is challenging and yielding an ambiguous signal 
across the genome. These results support proposed models of p53 scanning 
along DNA, prior to inductive signaling, in a gene-specific manner that 
determines downstream response [168]. 
 Intriguingly, p53-bound regions in hESCs undergoing differentiation were 
significantly enriched in core transcription factors OCT4 and SOX2 binding 
motifs (P < 10-16 and P < 10-12 respectively) (Figures 7A-B), whereas no OCT4-
SOX2 motifs were found in p53-bound genomic regions from pluripotent hESCs 
or those exposed to damage (Figures 7A-B). We performed a reciprocal 
analysis to detect any p53-motif within OCT4-SOX2 and NANOG enriched sites, 
using previously published ChIP-Seq datasets [134]. Our analysis revealed 
overlapping p53 response elements (p53REs) in both OCT4-SOX2 and 
NANOG datasets (Figure 8). The presence of consensus binding motifs for 
OCT4 and SOX2 in p53-bound regions suggests a possible interplay between 
these transcription factors in determination of specific stem cell states. 
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Figure 7. p53, OCT4-SOX2 motifs are enriched within p53 enriched sites 
 
A) p53 and OCT4 consensus motif sequence from TRANSFAC database [top], 
and matching enriched motifs under p53 peaks [bottom].  
B) The OCT4 motif is enriched in p53-bound regions in cells undergoing 
differentiation, but not in response to damage.  
Mof Name Corrected P-value
p53 9.3 E-235
Damage
Dierenaon
Mof Name Corrected P-value
p53 4.8 E-37
Pou5f1(OCT4) 5.9 E-16
SOX2 4.6 E-12
Untreated
Mof Name Corrected P-value
p53 1.19 E-5
Mof Dierenaon Damage
p53
Pou5f1 (OCT4) ------
A
B
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Figure 8. p53 motif is present in the genomic regions bound by OCT4 and 
NANOG 
 
Detected p53 motif in OCT4 (left-up) and NANOG (left-down) bound regions in 
pluripotent ES cells. p53 consensus binding motif in TRANSFAC database 
(right).   
p53 motif in OCT4 bound regions
p53 motif from TRANSFAC database
p53 motif in NANOG bound regions
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3.3 p53 targets developmental transcription factors during 
differentiation 
 Across the genome, a significant portion of p53 binding sites (42% for +RA 
and 28% for +Adr) are enriched (0.68 fold for +RA and 0.61 fold for +Adr over 
randomized binding sites) within 10kb of the nearest annotated transcription 
start site (TSS) (Figure 9A). Therefore, we used a 10kb window of distance 
from the p53-peak summit to the nearest gene TSS to call a p53 target gene 
(Figure 9B).  
 Similar to the identified binding sites between conditions, target-gene 
comparison analysis revealed only 22% overlap in identity (717 genes) between 
damage (1326 genes) and differentiation (3172 genes) (Figure 9B), suggesting 
distinct roles for p53 dependent on cellular environment. Gene-ontology (GO) 
analysis revealed a startling distinction between genes regulated by p53 during 
differentiation versus damage (Table 2). While most of the p53-targets during 
differentiation are categorized primarily as genes involved in development 
(particularly in neuronal development, a pathway which is triggered by the RA 
signaling) and transcription regulation (P < 10-6), damage-specific p53-targets 
are associated with cell migration and motility (P < 10-4) (Table 2). Highly 
studied p53 targets, e.g., CDKN1A, MDM2, are significantly (P < 10-6) 
represented in genes common to both differentiation and damage (Table 2).  
  
 42 
 
 
Figure 9. p53 targets distinct set of genes during differentiation and DNA-
damage in hESCs 
A) Distribution of p53 occupied regions relative to the nearest annotated TSS in 
hESCs undergoing differentiation or damage. 
B) Numbers of distinct and overlapping p53-target genes in hESCs undergoing 
differentiation and DNA damage.  
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Table 1. Response specific target genes are involved in different 
biological process 
GO term analysis revealed significant and diverse functions of p53 downstream 
target genes that are specific or shared in response to each treatment 
(differentiation and damage).  
Differentiation Specific Target Genes
Identifier GO Term Genes in the List
Total 
Genes P-value
GO:0045449 regulation of transcription 452 2601 1.56E-12
GO:0048598 embryonic morphogenesis 73 307 3.49E-07
GO:0030182 neuron differentiation 94 438 9.40E-07
GO:0007389 pattern specification process 64 267 1.50E-06
GO:0030900 forebrain development 42 152 3.16E-06
Damage Specific Target Genes
Identifier GO Term Genes in the List
Total 
Genes P-value
GO:0016477 cell migration 21 276 3.10E-04
GO:0051674 localization of cell 22 307 4.78E-04
GO:0048870 cell motility 22 307 4.78E-04
GO:0006928 cell motion 29 475 6.52E-04
GO:0007266 Rho protein signal transduction 7 38 9.29E-04
Overlapping Target Genes
Identifier GO Term Genes in the List
Total 
Genes P-value
GO:0042981 regulation of apoptosis 61 804 4.67E-07
GO:0043067 regulation of programmed cell death 61 812 6.42E-07
GO:0008629 induction of apoptosis by intracellular signals 13 54 6.91E-07
GO:0010941 regulation of cell death 61 815 7.29E-07
GO:0043065 positive regulation of apoptosis 39 430 1.39E-06
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 Next, we determined enrichment of protein domains encoded by p53-
target genes in each condition using InterPro terms of the GREAT functional 
annotation tool. Homeobox domains were revealed as differentiation targets (P 
< 10-13). This finding is consistent with the GO-term analysis results since the 
proteins encode Homeobox domains are evolutionary conserved and 
developmentally important transcription factors with the ability to bind DNA 
through their Homeobox domains. On the other hand, EGF-type domains were 
targeted in damage (P < 10-6) (Table 3), currently this domain’s significance 
remains to be known because of its presence in protein families what seems to 
be unrelated.  
 Several transcription factor families that regulate specification and 
development are highly represented as differentiation targets (Figure 10). 
These include members of the Homeodomain-box (HOX) gene family, which 
are activated as a first response to RA and regulate pattern formation during 
embryogenesis [96]; LIM homeobox (LHX) genes, which are involved in 
embryonic development and specifically neuronal differentiation [169]; the 
forkhead box (FOX) family of genes, which are involved in axial patterning and 
tissue development from all three germ layers [170]; the sex determining 
region-Y box (SOX) gene family that regulates cell-fate specification [171]; and, 
Zic family members (ZIC) that are important during neuronal development, 
mutations of which cause a wide variety of congenital malformations [172] 
(Figure 10). These findings suggest that, during differentiation of hESCs, the 
regulatory influence of p53 is extensive and amplified by targeting transcription 
factors that promote a committed cellular state. 
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Table 2. Significant number of p53 targets during differentiation possess 
homeobox domain 
Enrichment analysis of protein domains encoded by p53 downstream target 
genes that are specific or common in differentiation and DNA-damage. Top 
categories from each dataset are listed.  
Enriched protein domains in Differentiation targets
Identifier INTERPRO Term-Name Genes inthe List
Total
Genes
Binomial 
FDR Q-value
IPR009057 Homeodomain-like 109 314 7.62E-19
IPR012287 Homeodomain-related 106 304 8.81E-19
IPR001356 Homeobox 93 237 2.26E-17
IPR017970 Homeobox, conserved site 79 183 8.72E-16
IPR020479 Homeobox, region 40 87 1.65E-13
Enriched protein domains in Damage targets
Identifier INTERPRO Term-Name Genes in the List
Total 
Genes
Binomial 
FDR Q-value
IPR001881 EGF-like calcium-binding 30 108 7.56E-07
IPR013091 EGF calcium-binding 25 87 1.29E-06
IPR013032 EGF-like region, conserved site 41 197 3.23E-06
IPR000152 EGF-type aspartate/asparagine hydroxylation site 28 102 6.64E-06
IPR018097 EGF-like calcium-binding, conserved site 27 99 8.63E-06
Enriched protein domains in Overlapping targets
Identifier INTERPRO Term-Name Genes in the List
Total 
Genes
Binomial 
FDR Q-value
IPR020465 Tumour necrosis factor receptor 10 4 4 1.11E-03
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Figure 10. Developmental transcription factor families are targeted by p53 
during hESC differentiation 
 
Gene families of developmental transcription factors are targets of p53 during 
differentiation. p53 (green circle) regulation is linked to individual transcription 
factors (cyan circles), shown grouped by family.  
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3.4 p53 binding sites coincide with ESC transcription factors 
during differentiation 
 Developmental genes are often poised in ESCs by core pluripotency 
factors and bivalent histone modifications [35,36,37,38]. In addition, our motif 
analysis revealed that OCT4 and NANOG motifs are enriched at differentiation-
induced p53 binding sites but not in DNA damage binding sites. Therefore, we 
analyzed the distribution of p53 binding sites, across four representative HOX 
loci of the human genome and compared them to OCT4, NANOG and 
H3K27me3 enrichment sites (Figure 11). A circular plot of human chromosomes 
2, 7, 12 and 17, representing a ~100 Kb region of each HOX cluster, illustrates 
enrichment of OCT4, NANOG and H3K27me3 in pluripotent hESCs (Figure 11). 
During differentiation p53 binds (21 binding sites to 11 identified target genes) 
in and around these HOX clusters. In contrast, there is only one intergenic p53-
bound site induced by DNA damage at these loci. These findings suggest that, 
during differentiation of hESCs, the regulatory influence of p53 is extensive and 
amplified by targeting transcription factors that promote a committed cellular 
state.  
  
  
Figure 11. Binding profiles of p53, OCT4 and NANOG around human HOX 
loci 
  
Circos plot of four human HOX gene clusters showing differential binding 
patterns of OCT4 (blue), NANOG (red), 
hESCs and p53 (damage:yellow, differentiation:orange)
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 Overlap between core transcription factors and differentiation-induced p53 
binding sites around the HOX clusters lead us to investigate whether binding 
sites of mentioned factors overlap in a region specific or genome-wide fashion. 
Obtained results indicated that overlap between p53, OCT4 and NANOG 
binding sites is widespread across the genome, as ~50% of the 1000 highest 
confidence, differentiation-bound p53 sites are occupied by OCT4, NANOG or 
both in pluripotent hESCs; only a small fraction (~12%) overlap with damage-
specific p53 sites (Figure 12A). Randomization tests demonstrated that 
percentage of differentiation-induced p53 binding sites that overlap with OCT4 
and/or NANOG sites is significantly higher than those observed with randomly 
generated genomic sites, whereas overlap between damage-specific p53 sites 
and OCT4 or OCT4:NANOG binding sites are within random range (Figure 
12B).  We extended co-occupancy analysis to genome-wide by ranking each 
set of p53-binding sites (differentiation- and damage-induced) based on their 
enrichment scores and performed the intersection analysis for each segment. 
Results showed a significantly higher ratio of p53:OCT4:NANOG overlap and 
stronger p53-peaks at differentiation- versus damage-induced binding sites 
(Figures 13-14).  
  
  
 Figure 12. p53 binding sites coincide with ESC transcription factors 
during differentiation 
A) Overlap of top p53 
undergoing differentiation or damage. 
B) Plots indicate percent overlaps along the x
expected overlap with random data. 
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Figure 13. Association of OCT4 and/or NANOG binding sites with p53 
 
Percent overlap among OCT4, NANOG and enrichment based top ranked p53 
bound regions in hESCs undergoing damage (left) or differentiation (right). 
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In order to compare the raw signal intensities we performed heat map 
analysis, which revealed that ChIP-Seq signal intensity of OCT4 and NANOG at 
genomic sites bound by p53 exclusively during hESC differentiation is notably 
higher than their signals around p53-damage specific sites (Figure 14A). This 
suggests that a specific subset of genes (mostly developmental transcription 
factors) is kept in a repressed state by OCT4/NANOG during pluripotency and, 
in response to RA, p53 occupies nearby to regulatory regions of these genes to 
promote hESC differentiation.  
Binding profiles and comparison of p53 and NANOG peaks reveal that 
OCT4 enrichment at p53 peaks, established during differentiation, is of the 
same magnitude as at NANOG sites (Figure 14B). However, NANOG 
enrichment is stronger at OCT4 binding sites than p53 (Figure 14C). The 
absence of OCT4 or NANOG at damage-induced p53 sites suggests that p53 
plays distinct regulatory roles in hESCs, which are dictated by external stimuli. 
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Figure 14. NANOG and OCT4 binding strengths are much higher at 
differentiation specific sites 
 
Heat map of binding signals of p53 (damage and differentiation), OCT4 and 
NANOG within -500bp to +500 bp of p53 condition-specific peak summits. 
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Figure 14. NANOG and OCT4 binding strengths are much higher at 
differentiation specific sites 
Aggregate plots shows average OCT4 (B) and NANOG (C) enrichment profiles 
around central position of p53 (Damage:green, Differentiation:Red) and 
NANOG/OCT4 (Purple) binding regions.  
B
C
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3.5 Transcription of development genes is dependent on p53 
 To uncover the functional consequences of p53 interactions with 
chromatin, we performed microarray-based gene expression analysis of hESCs 
undergoing differentiation and integrated these data with our p53 ChIP-Seq 
dataset (Figure 15). Expression analysis revealed a total of 1220 up- and 1221 
down-regulated genes (with FDR-corrected p-value less than 0.05) during 
differentiation of hESCs compared to pluripotent state. Intersection with our p53 
ChIP-Seq data revealed that more than 25% of genes regulated during 
differentiation (262 down- and 361 up-regulated) are bound by p53. We next 
sought to identify differentiation-specific p53 targets by eliminating genes that 
are targeted by p53 during DNA damage, as a result 198 down- and 271 up- 
regulated genes were assigned as p53’s differentiation-specific targets and 
further analyses performed on this set of genes (Figure 15).  
  
  
 
 
 
Figure 15. Integration of gene expression and p53 binding data in 
differentiating hESCs 
 
Volcano plot of microarray gene
RefSeq gene; in RA treated samples with average log2 fold change compared 
to pluripotent hESCs and 
correspond to genes bound by p53: significantly up
(green) p53 targets are highlighted. Target genes overlapping with damage 
datasets are discarded. 
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GO-term analysis of RA-down-regulated p53 targets revealed that these 
genes are enriched for cell motion and mesodermal differentiation (Figure 16). 
These genes include FOXO3: essential activator of mesodermal marker 
Brachyury [173]; KLF6: associated with hematopoiesis [174]; chromatin 
modifiers HDAC5 and HDAC9: class II HDACs with critical functions in heart 
development [175]; and, telomere repeat binding factor TERF1: a telomere 
maintenance factor associated with pluripotency [176] (highlighted in Figure 15).  
 
Figure 16. GO functional classifications of down-regulated p53 
 
Heat map, generated for differentiation-specific p53 target genes, reveals up- or 
down-regulated targets during differentiation compared to pluripotent hESCs. 
The GO-term analysis of down-regulated p53-target genes is shown.   
Untreated Differentiation
log2(fold change)
Regulation of cell motion
Lymphocyte differentiation
Negative regulation of biosynthetic process 
Regulation of transcription
B cell differentiation
-log10(p-value)
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RA-up-regulated p53 targets revealed significant (P<10-5) representation 
in neuro-ectodermal development, embryonic morphogenesis and pattern 
specification categories (Figure 17). These genes include homeobox domain 
genes (HOXA1, HOXA3, HHEX and HOXB1), developmental transcription 
factors (GATA2, LHX8, ZIC1 and TCF7L2) and RA nuclear receptors (RARA 
and RARB) (highlighted in Figure 15). Several of these genes are repressed by 
Polycomb complexes and poised by core pluripotency factors in pluripotent 
hESCs [17], but a role for p53 in their activation during differentiation has not 
previously been reported. 
 
Figure 17. Up-regulated p53 targets are involved in developmental 
processes 
Heat map, generated for differentiation-specific p53 target genes, reveals up- or 
down-regulated targets during differentiation compared to pluripotent hESCs. 
The GO-term analysis of up-regulated p53-target genes is shown. 
Untreated Differentiation
log2(fold change)
Pattern specific process
Embryonic morphogenesis
Embryonic organ development
Regulation of nervous system development
Endocrine system development
Regulation of neurogenesis
Regionalization
Regulation of cell development
Positive regulation of gene expression
-log10(p-value)
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 We performed quantitative RNA and p53 ChIP-PCR analyses of selected 
genes (Figure 15), to assess the impact of p53 binding and to validate the 
outputs of our genome-wide assays (Figures 18-19). RA treatment for 2 and 4 
days resulted in significant activation of genes belonging to HOX and GATA 
families (Figure 18A). Four days of RA increased expression of these genes, as 
well as developmental transcription factors: TBX5, homeobox genes MSX2 and 
GBX2, hedgehog receptor PTCH1, Notch co-repressor TLE3, polycomb protein 
BMI1 and histone H3K36 demethylase KDM2B (Figure 18B). Observed 
differences in the timing of target gene inductions may be due to a cascade of 
transcriptional events, where certain genes are activated as early as two days 
during RA-mediated hESCs differentiation, whereas it takes others longer to be 
induced.  
 RA-mediated transcriptional activation of selected genes is dependent on 
p53, since hESCs transfected with siTP53 showed no significant activation of 
these genes with RA-treatment. In contrast, p53 induction by DNA damage had 
no significant effect on these genes (Figures 18A-B). Expression of well-known 
p53 pathway genes CDKN1A and MDM2 was induced during both 
differentiation and damage in a p53-dependent manner, confirming the GO 
analysis results (Table 2) which indicated that p53-pathway genes are enriched 
in the shared targets under these two conditions. (Figure 18C). 
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Figure 18. Transcription of developmental genes during RA-mediated 
differentiation is p53-dependent 
RT-qPCR analyses of selected genes in hESCs after 4 d of RA-treatment with 
TP53 or control non-targeting siRNA. Error bars represent standard deviation 
from three replicates (* <0.05, ** <0.01). [data contributed by Abhinav Jain] 
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 We used positional weight matrixes (PWMs) obtained from transcription 
factor motif analysis (Figures 7-8) of p53-enriched genomic regions to map 
OCT4, NANOG and p53 binding elements at specific developmental genes: 
HOXA1, PTCH1 and TBX5 (Figure 19A). ChIP-qPCR analyses revealed robust 
enrichment of p53 binding, within two days of RA exposure, at the p53REs of 
PTCH1, HOXA1, TBX5 and CDKN1A (Figure 19B). Importantly, p53-
enrichment at these sites (PTCH1, HOXA1 and TB5) is RA-specific, since no 
significant changes observed in response to DNA-damage. On the other hand, 
in both conditions p53 enriched around the CDKN1A promoter, this suggests 
that developmental gene targeting is specific to p53’s role in hESC 
differentiation (Figure 19B).  
 To assess whether OCT4 and p53 co-occupy the overlapping binding sites, 
we performed sequential ChIPs (re-ChIP) on OCT4-enriched chromatin 
fragments from hESCs treated with RA for 2 days (Figure 19C). RA robustly 
induced p53 enrichment and co-occupancy at OCT4-associated regions of 
PTCH1 and TBX5, roughly equivalent to the increase in p53 association 
induced by RA (Figure 19C). The OCT4-OCT4 re-ChIP indicates equal 
efficiency of OCT4 binding to chromatin sites in both untreated and 2-day RA-
treated hESCs. However, the distance between p53 and OCT4 binding sites on 
HOXA1 (> 500bp) is greater than the vast majority of our fragmented chromatin 
length (Figure 19A) that’s why re-ChIP experiments was not feasible for this 
genomic locus.  
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Figure 19. Enrichment of p53 at developmental genes results in activation 
A) Tracks represent normalized p53 sequence tag enrichments (numbers 
indicate distance from TSS). Binding location of NANOG (red) and OCT4 (blue) 
are shown at the bottom of the tracks.  
B) ChIP-qPCR analysis of p53 occupancy at select target genes during 
differentiation [top] or DNA damage [bottom]. [data contributed by Kendra Alton] 
HOXA1
25
1
NANOG
OCT4
p53 (+4526)
1kb
PTCH1
p53 (-4121)
NANOG
OCT4
25
1
3kb
TBX5 NANOG
OCT4
25
1
5kb
p53 (+4713)
A
B
PTCH1 HOXA1 TBX5 CDKN1A
0
1
2
3
4
6
8
10 UntreatedRA 2D
Fo
ld
 
C
ha
n
ge
: 
p5
3
PTCH1 HOXA1 TBX5 CDKN1A
0.0
0.5
1.0
1.5
2.0
2.5
Untreated
Adr
Fo
ld
 
Ch
an
ge
: 
p5
3
ChIP:p53
ChIP:p53
 63 
 
 Developmental genes are held poised in ESCs by repressive histone 
marks (H3K27me3), which are lost upon differentiation [2]. We generated 
hESCs stably expressing non-target (shControl) or shRNA against p53 
(shTP53) to determine whether RA-activated p53 had an impact on levels of 
H3K27me3 at the promoters and/or p53-response elements (p53RE) of PTCH1, 
TBX5 where p53 co-localizes with OCT4 at 2 days of RA treatment (Figure 
19C). Stable integration of shTP53 resulted in a significant knockdown of p53 
protein and failure to elicit an RA-response, since no reduction in AP-staining 
and OCT4 protein was observed in shTP53-hESCs as compared to control 
(data not shown). In response to RA, H3K27me3 levels are significantly 
reduced at PTCH1 and TBX5 in shControl cells, whereas no change in 
H3K27me3 levels were observed in hESCs stably depleted of p53 (shTP53) 
(Figure 19D).  
 
 Together, these results suggest that RA-induced signals of differentiation 
mobilize p53 to bind and activate a number of chromosomal locations around 
the developmentally important transcription factors that are poised by 
OCT4/NANOG in pluripotent hESCs by altering the chromatin status. 
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Figure 19. Enrichment of p53 at developmental genes results in activation. 
C) p53 enrichment on OCT4 bound regions after sequential ChIPs. Quantitative 
PCR of chromatin fragments enriched by p53, OCT4 and sequential ChIP of 
hESCs, treated with RA for 2 days.  DNA enrichments at indicated target genes 
were determined as fold change in % input, compared to untreated hESCs.  
D) Histone H3K27me3 status on gene promoter or p53RE of PTCH1 and TBX5 
in hESCs treated with RA for 2 days. Error bars represent standard deviation 
from three replicates (* <0.05, ** <0.01). [data in Figs 19C-D contributed by 
Kendra Alton]  
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3.6 p53 targets lose repressive histone marks during 
differentiation 
 We next sought to determine if changes in bivalent chromatin structure 
occur globally around the p53-target genes during differentiation, by analyzing 
genome wide histone status utilizing ChIP-Seq method for active (H3K4me3) or 
repressive (H3K27me3) histone marks in hESCs undergoing differentiation. To 
define histone tail modifications at the promoters of p53 targets, we first 
categorized the p53’s differentially expressed targets as those that have 
overlapping OCT4 and/or NANOG binding sites, and the ones that are targeted 
by p53 only (Figures 21-22). Gene expression profiling revealed that while the 
average expression of the two sets are comparable, p53 gene targets that are 
shared with those bound by OCT4 and/or NANOG prior to differentiation are the 
most significantly changed (up- or down-regulated) genes (Figures 21A and 
22A). Consistent with the biological functions of all differentiation-specific p53- 
targets (Table 2), GO-term analysis for up-regulated p53 targets with 
overlapping OCT4 and/or NANOG sites revealed genes responsible for pattern 
specification, embryonic morphogenesis and development (Figure 20B). 
On the other hand, down-regulated p53 targets with overlapping OCT4 
and/or NANOG sites are involved in mesodermal differentiation, metabolism 
and cell motion (Figure 21B).  
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Figure 20. p53’s overlapping targets with OCT4 and NANOG are more 
robustly expressed during differentiation 
A) Violin plots representing fold changes in expression of p53 targets up-
regulated during differentiation. Genes that have p53 binding sites overlapping 
with OCT4 and/or NANOG (p53_OCT4_NANOG) (blue); or only p53 binding 
sites (green).  
B) The GO-Term analysis of overlapping targets of p53_OCT4_NANOG is 
shown.  
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Figure 21. GO functional classification results down-regulated p53 targets 
with overlapping OCT4 and/or NANOG sites 
A) Violin plots representing fold changes in expression of p53 targets down-
regulated during differentiation. Genes that have p53 binding sites overlapping 
with OCT4 and/or NANOG (p53_OCT4_NANOG) (blue); or only p53 binding 
sites (green).  
B) The GO-Term analysis of overlapping targets of p53_OCT4_NANOG is 
shown.  
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Genome wide profiling of average histone modifications confirmed that 
up-regulated p53-targets, overlapping with OCT4 and/or NANOG sites, are 
associated with bivalent histone marks (H3K4me3 and H3K27me3), which are 
significantly altered during differentiation (high H3K4me3, low H3K27me3), as 
compared to down-regulated targets (Figures 22A and 22C). However, genes 
targeted by p53 only gain H3K4me3 marks without a significant change in 
H3K27me3 status (Figures 22B and 22D).  
Taken together, these results suggest that p53 plays an active role, 
possibly cooperating with core pluripotency factors, during differentiation of 
hESCs by recruitment of chromatin modifying complexes, which decrease 
repressive histone marks of specific developmental genes held poised in 
pluripotent stem cells. 
  
 69 
 
 
Figure 22. Bivalent chromatin marks around promoter regions of p53 
target genes in pluripotent and differentiating hESCs 
 
Aggregate plots showing profiles of histone modifications around +/- 2KB from 
transcription start site (TSS) of up-regulated p53_OCT4_NANOG overlapping 
gene targets (A) and only p53 targets (B). 
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Figure 22. Bivalent chromatin marks around promoter regions of p53 
target genes in pluripotent and differentiating hESCs. 
Aggregate plots showing profiles of histone modifications around +/- 2KB from 
transcription start site (TSS) of down-regulated p53_OCT4_NANOG 
overlapping gene targets (A) and only p53 targets (B). 
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CHAPTER 4 DISCUSSION AND FUTURE DIRECTIONS 
4.1 Discussion 
Studies of p53 are extensive; specifically its functions in cell cycle 
regulation and apoptosis have been scrutinized for several decades in 
transformed somatic cells [115,177,178]. The broader potential in regulatory 
roles of numerous cellular processes was only recently appreciated. For an 
example, p53 has been implicated in regulating cellular metabolism, 
deregulation of p53 leads to compromised oxidative phosphorylation chain, 
which is also known as Warburg effect, one of the hallmarks of cancer cells 
[179,180]. 
 On the other hand, a limited knowledge of p53’s function in non-
transformed cells; especially in highly proliferative undifferentiated cells, such 
as embryonic stem cells, therefore its role in development and control of cell-
fate is largely unknown [116]. In order to dissect p53’s functions during 
transcription in human ESCs cultured under different culture conditions 
(Adriamycin for DNA damage and RA for differentiation), we performed 
genome-wide p53-chromatin binding assays along with gene expression 
microarrays. Integration of the data output from these comprehensive methods 
revealed that the RA-mediated p53-response during differentiation is highly 
distinct from the stress-responsive events occurring downstream of DNA 
damage in hESCs. During early differentiation, p53 activates the expression of 
several developmental transcription factor families, many of which possess 
homeobox protein domains. This activated cascade of transcription factors 
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amplifies the functional effects of p53 induction beyond the transient time period 
when p53 protein is elevated [140].  
Differentiation-specific p53-activated genes include members of HOX, 
FOX, SOX, T-box (TBX) and Chromobox (CBX) gene families that are involved 
in differentiation and development. HOX genes are known to be involved in 
patterning during embryogenesis as major developmental factors [181], for 
example HOXA1 is essential for RA-mediated neural differentiation [98]. FOX 
family members have been implicated in formation of different organs during 
development [170], such as liver. Mutations in SOX family genes impair proper 
differentiation and have been related to several developmental disorders [171]. 
Members of the CBX family, particularly CBX2 and CBX4 are part of the 
Polycomb complex [182] and are vital for cell-fate determination [172]; whereas 
the TBX gene family regulates a diverse range of developmental processes 
from early body planning to late organogenesis [183].  
One facet of p53 gene regulation involves repression of some 
transcription factors and epigenetic modifiers while activating another set of 
developmental genes required for RA-mediated neuro-ectodermal lineage 
specification. Some of the down-regulated p53 targets include regulators 
required for mesodermal lineage specification such as, transcription factors 
FOXO3 [173], HEY1 [184] and KLF6 [174]; histone deacetylases HDAC5, 
HDAC6 [175] and chromatin remodeler CHD7 [185]. Several proteins that are 
involved in transcriptional repression are also targeted by p53 for down-
regulation including telomere repeat factor TERF1 [176], PcG complex 
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compotent RNF2 [186] and Chromobox family member CBX5 [187]. Taken 
together, p53 might play a significant role in lineage determination by RA-
induced p53-mediated repression and activation of specific genes in hESCs. 
 Remarkably, our motif finding analysis revealed that the differentiation-
specific p53-bound sites are also enriched in OCT4:SOX2 motif. Moreover, 
comparison of binding sites showed that more than half of the strongest p53-
bound sites are coincident with binding sites of core pluripotency factors OCT4 
or NANOG, or both, in pluripotent hESCs. This suggests that there could be 
interplay between p53 and the core pluripotency factors, specifically during 
early hESC differentiation since this phenomenon is not observed for p53’s 
binding sites during DNA-damage. Our experimental validations showed that 
three developmental genes HOXA1 [98], PTCH1 [188] and TBX5 [189] are up-
regulated during hESC differentiation in a p53-dependent manner. Chromatin 
immunoprecipitation (ChIP) studies revealed that OCT4 and NANOG are bound 
at or in the proximity of p53-binding sites at these developmental genes during 
differentiation. Sequential-ChIP assay confirmed that during differentiation p53 
indeed co-localizes to these regions, which are bound by OCT4. However, our 
current findings cannot conclude whether p53 recruitment ultimately results in 
displacing the bound OCT4 and/or NANOG proteins at the regulatory sites or 
these factors synergistically bring other chromatin modifiers to those loci, 
thereby activating down-stream targets expression. Elucidation of the exact 
mechanism requires further experiments.  
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Given the importance of bivalent domains in pluripotency maintenance 
and establishment of cell fate [35,36,37,38], we profiled the bivalent histone 
modifications (H3K4me3 and H3K27me3) in pluripotent and differentiating 
hESCs by ChIP-Seq. Our analyses revealed that up-regulated p53 targets, 
which are also bound by OCT4 and/or NANOG, are kept poised in ESCs by 
bivalent modifications and during differentiation promoter regions of these 
genes acquire more H3K4me3 mark while losing their H3K27me3 modifications. 
Furthermore, we tested if p53 has any roles regulating the chromatin 
modification switch near its target genes during differentiation. Notably, PTCH1 
and TBX5 gene promoters could not lose their promoter-associated H3K27me3 
marks during differentiation in p53-depleted hESCs. These results suggest that 
p53 might play a significant role in modifying chromatin structure at its poised 
target genes by coupling with an unknown H3K27 demethylase complexes 
during hESC differentiation. 
 The shared target genes of p53 during differentiation and DNA damage 
response are enriched in cell cycle regulation. p53-regulated cell-cycle control 
pathways play significant roles in both during hESC differentiation, by impeding 
cell cycle and leading differentiation [140], and DNA-damage repair by blocking 
the self-renewal pathway in order to prevent accumulation of chromosomal 
damage. Metabolism, another common GO term for conserved p53 target 
genes, suggests the link between p53 and metabolism could be as crucial as 
cell cycle pathways during both development and tumor suppression [179,190]. 
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The most interesting GO terms that are identified specifically in p53 
targets during DNA-damage, cell motion and cell migration, are the signature 
characteristics of metastatic carcinomas. For example, damage specific p53 
gene targets listed under GO category of cell motion, FGF2 and LRP8, have 
been grouped into the stem-like gene expression sets that are only observed in 
p53 loss-of function cancers [126]. Moreover, two other cell motion-associated 
p53 targets, MMP14 and TNFRSF12A, are classified in epithelial to 
mesenchymal transition (EMT), which is a required step for metastasis [191], 
genes in prostate cancers [126]. Further examination of DNA-damage specific 
targets provides an opportunity to dissect profiles of aggressive metastatic 
tumors by monitoring changes in activities of these genes as an indication of 
deregulated p53-pathway.  
 Our study unveiled p53’s important regulatory functions in the human 
embryonic differentiation, which does not align with the previously reported 
findings about p53’s role in mESCs. Previous reports have shown that p53 
binds to the promoter of Nanog in mESCs and suppresses its transcription, 
which leads to differentiation of mESCs [131]. Instead, we did not detect any 
p53 binding sites nearby NANOG regulatory regions in our p53 ChIP-Seq 
results in hESCs. Secondly, Li et al. recently reported that in response to DNA-
damage p53 both activates differentiation-associated genes and represses ES-
specific genes in mESCs [133]. However, our results in hESCs indicate that p53 
targets a different set of genes during differentiation versus DNA-damage and 
only differentiation-specific p53 target genes are related with development and 
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specification. These findings implicate that unlike mouse ESCs, p53 does not 
repress pluripotency factors in human ESCs, yet only mediate expression of 
developmental genes. Moreover, p53’s pro-differentiation role takes place 
under different environmental conditions (DNA-damage in mouse and 
differentiation-initiation in human ESCs) in different species (Figure 23, p53 
targets several Hox genes upon DNA-damage in mESC but binds to only a 
single intergenic region in human HOX cluster loci after exposed to the same 
stress in hESCs). Observed species-specific differences in p53’s functions in 
two organisms may be attributed to the different embryonic development stages 
of mouse and human ESCs [192]. In parallel, mounting evidences demonstrate 
a rapid evolutionary turnover for transcription factor binding sites on a genome-
wide scale between species which results in regulation of a diverse set of 
genomic elements in different species by the same transcription factor 
[134,193,194,195,196]. 
 Given the p53’s significant role in promoting hESCs differentiation, 
viability of p53-null mice and formation of teratomas in SCID mice from p53-null 
hESCs raises some interesting questions [197]. In this case, we believe 
compensation of p53 functions in development would likely to be executed by 
the structurally related protein family members, p63 and p73 [198]. Notably, 
several developmental abnormalities such as neural tube malformations or 
defects in spermatogenesis and embryo implantation have been reported 
despite the fact that p53-null mice are not embryonic lethal [116]. This suggests 
that p53’s functions are imperfectly compensated by other factors, but whether 
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p63 or p73 isoforms target any or all p53 downstream targets in hESCs 
differentiation remains to be investigated. 
  
 Figure 23. Species-specific binding of p53 in different environmental 
Human (hs) and mouse (mm) HOX gene
plot. Green track represents repressive H3K27me3
regions in mESCs and hESCs
underlying structures of HO
(differentiation) rectangles represent enriched p53 binding sites in these two 
conditions. Purple heatmap shows the PhastCons scores around the displ
regions. Ribbons show synt
(orange ribbons presents homologous p53 binding sites between DNA
damaged mESCs and differentiating hESCs, whereas yellow ribbons are for 
shifted sites for same gene targets in mESCs and hESCs).
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4.2 Future Directions 
 Our mapping results revealed that for both DNA damage and 
differentiation of hESCs, p53-binding sites are enriched mostly in intergenic 
regions of the genome where non-coding RNA expression initiates (more than 
50% of total binding sites in DNA damage and differentiation are located in 
gene desert regions). Binding sites of p53 around these intergenic sites gain 
significant value when the recent reports about ncRNAs (lncRNAs and miRNAs) 
and their effects in pluripotency and differentiation are taken into consideration 
[62]. Additional studies are required to confirm p53’s regulatory significance in 
regulation of ncRNAs expression and possible down-stream roles of those p53-
regulated RNAs in hESCs differentiation. 
 Members of p53 family, p63 and p73, can also regulate the gene-
expression program that is mainly directed by p53, in which p73 had been 
shown to serve as a back-up protein for maintaining genomic integrity when p53 
functions are compromised [199]. These proteins are also implicated in 
important developmental processes [200] such as p63 in epithelial ESC self-
renewal [201] and p73 during neural cell differentiation [202]. Notably, 
significant portion of amino acids in DNA-binding domains, ~85%, are 
conserved among p53 family members, further reports revealed that p63 and 
p73 co-occupy target sites with a shared consensus motifs similar to those of 
p53 [203]. Therefore, obtaining genome-wide binding maps of p63 and p73 in 
differentiating or DNA-damaged hESCs would eventually lead a more 
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comprehensive understanding of the roles of this tumor-suppressor protein 
family role in human development.  
 Understanding the differences in regulatory networks for balancing 
pluripotency and differentiation between mouse and human ESCs, it would be 
important to establish genome-wide p53 binding sites in differentiating mouse 
ES and epiblast stem cells. Mouse epiblasts are considered to be more 
developmentally close to human ESCs [137,192] and thus determination of 
p53’s binding sites will help to understand the regulatory functions of p53 in 
development of these two organisms.  
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